Cancer lab to evaluate bioequivalence of nanosimilars

05:39 EDT 23 Sep 2016 | Generics and Biosimilars Initiative

The Frederick National Laboratory for Cancer Research (Frederick National Lab) announced on 10 June 2016 that it was collaborating with the US Food and Drug Administration (FDA) on the characterization of nanosimilars.

Original Article: Cancer lab to evaluate bioequivalence of nanosimilars


More From BioPortfolio on "Cancer lab to evaluate bioequivalence of nanosimilars"

Quick Search

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...